Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06504381 · ClinicalTrials.gov registry record · Phase 1
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
A Phase 1 study of High Grade Glioma and MGMT-Unmethylated Glioblastoma, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 5
- Study locations
NCT06504381 is a Phase 1 study of High Grade Glioma and MGMT-Unmethylated Glioblastoma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 70 participants, roughly in line with the 64-participant average among 42 other High Grade Glioma trials with a reported enrollment target. The trial reports 5 study locations across 3 states.
The verdict
NCT06504381, a Phase 1 study of High Grade Glioma and MGMT-Unmethylated Glioblastoma, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate whether treatment with DB107-RRV in combination with DB107-FC when added to standard of care provides clinical benefit to newly diagnosed HGG when compared to historical performance previously determined in well controlled clinical trials published in the peer reviewed literature. This study is going to be conducted in newly diagnosed HGG patients receiving with maximum surgical resection treatment followed by radiation and temozolomide treatment using the established Stupp Protocol for O6-methylguanine-DNA methyl-transferase (MGMT) methylated patients or radiation therapy for MGMT unmethylated patients.
Conditions Studied
Interventions
- DRUG Temozolomide
- PROCEDURE Magnetic Resonance Imaging (MRI)
- RADIATION Radiation Therapy (RT)
- GENETIC DB107-RRV
- DRUG DB107-FC
Study Locations (5)
California
- University of Southern California - Los Angeles
- University of California, San Diego - San Diego
- University of California - San Francisco
Florida
- University of Miami - Miami
New York
- Northwell Health - Lake Success
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-01-08 |
| Est. Completion | 2042-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06504381
The ClinicalTrials.gov registry entry for NCT06504381 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 64-participant average among 42 other High Grade Glioma trials with a reported enrollment target. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with High Grade Glioma appearing as the primary indexed condition, and to 5 interventions - of which Temozolomide is the first listed.
NCT06504381 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06504381 about?
NCT06504381 is a clinical study titled "DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma". This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate whether treatment with DB107-RRV in combination with DB107-FC...
What is the current status of trial NCT06504381?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2025-01-08. Estimated completion is 2042-01-31.
What conditions does trial NCT06504381 study?
This clinical trial studies the following conditions: High Grade Glioma, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma.
What interventions are being tested in trial NCT06504381?
The interventions under investigation include: Temozolomide (DRUG), Magnetic Resonance Imaging (MRI) (PROCEDURE), Radiation Therapy (RT) (RADIATION), DB107-RRV (GENETIC), DB107-FC (DRUG).
Who is sponsoring clinical trial NCT06504381?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06504381 being conducted?
This trial has 5 study locations across California, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
STARLITE for Unresectable High-Grade Gliomas
RECRUITING · Phase 1
-
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RECRUITING · Phase 1
-
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
RECRUITING · Phase 1
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
-
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
RECRUITING · Phase 1
-
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.